NeoGenomics, Spotify, Opko, Appian, Meta Trending With Analysts

Analysts are intrested in these 5 stocks: ( (NEO) ), ( (SPOT) ), ( (OPK) ), ( (APPN) ) and ( (META) ). Here is a breakdown of their recent ratings and the rationale behind them.

NeoGenomics is suddenly back on the radar, with analyst Puneet Souda upgrading NEO to Buy and hiking the price target from $12 to $25. He argues the oncology diagnostics specialist is finally delivering on its “one‑stop shop” promise, powered by a shift to higher‑value NGS tests, stronger execution from a now‑stabilized management team, and profitability that looks set to improve.

Souda sees 10% annual revenue growth as conservative, noting NGS already makes up about a third of the mix and is growing above 20%, helped by new offerings like PanTracer and RaDaR MRD. With management prioritizing higher pricing, rolling off low‑value contracts, expanding the sales force, and targeting margin expansion, he believes NEO’s valuation remains attractive relative to its growth and EBITDA outlook.

Spotify is also catching a more positive tone, as Barton Crockett lifts SPOT to Buy despite trimming his price target to $500. The first quarter matched revenue expectations and delivered solid user gains, with premium subscribers at 293 million and monthly active users climbing to 761 million, while margins improved even as operating costs surprised to the upside.

Crockett thinks the stock’s pullback reflects disappointment around margins and fears of AI competition, but he sees Spotify as the dominant gateway to artists rather than a victim of AI disruption. With AI‑driven features like AI DJ and SongDNA gaining traction, price hikes holding without spiking churn, and potential upside from new pricing tiers and stronger ad tools, he believes the long‑term growth story remains compelling.

In sharp contrast, Michael Petusky has turned cautious on Opko Health, cutting OPK to Hold after a weaker‑than‑expected first quarter and ongoing struggles at its BioReference diagnostics arm. Revenue and EPS both missed forecasts, BRH posted another sizable operating loss, and even the promising 4KScore test saw a year‑over‑year revenue decline.

Petusky still sees some long‑term potential in OPKO’s mix of diagnostics and pharma, but he doubts the company can bring BRH to break‑even this year and views the upper end of 2026 revenue guidance as unrealistic. With the outlook now hinging on a sharp second‑half acceleration that may not materialize, he finds little reason to expect the stock to move meaningfully higher in the near term.

Appian has also lost some of its shine with analysts, as Sanjit Singh downgrades APPN to Hold and cuts the price target to $25. He still believes Appian is a credible player in process automation with solid execution and an interesting AI story, but warns that investor skepticism toward seat‑based software models has grown since his earlier upgrade.

Singh argues that a sustained re‑rating will require clearer proof that Appian can accelerate top‑line or cloud growth, successfully shift toward more usage‑based pricing, and show that its AI capabilities are driving meaningful monetization. Until there is broader confidence that Appian can navigate AI‑driven competition and evolve its model, he sees the shares as fairly valued around peer multiples.

Meta Platforms rounds out the list with a more cautious stance from Doug Anmuth, who downgrades META to Hold and trims his target to $725. He acknowledges Meta’s impressive 33% revenue growth supported by AI‑enhanced advertising, rising engagement, and powerful network effects, but worries that the company faces a tougher road to justify massive AI infrastructure spending.

Anmuth points out that rivals like Google and Amazon have clearer paths to monetizing AI investment through their cloud businesses, while Meta is boosting capex to as much as $145 billion in 2026 and potentially driving free cash flow negative in the coming years. Until investors see more visibility into Meta’s AI roadmap, agentic products, and new revenue streams beyond ads, he expects the stock to remain under pressure despite its strong core ad business.